Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world

doi:10.3748/wjg.v29.i41.5641

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3812)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1805

Figures (1-4)

235

Tables (1-5)

218

Sum=2374

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

172

Download

407

Sum=579

Publishing Process of This Article

Item

Count

Browse

179

Download

540

Sum=719

Nov 7, 2023 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Nov 7, 2023; 29(41): 5641-5656
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641

Table 1 Patient baseline characteristics (n = 55)

Characteristics	n (%)
Age (yr)
Median	61
Range	44-74
Sex
Male	43 (78.2)
Female	12 (21.8)
Tumor location
Upper esophagus	19 (34.5)
Middle esophagus	25 (45.5)
Lower esophagus	11 (20)
Clinical stage
II	10 (18.2)
III	19 (34.5)
IV	26 (47.3)
Subgroups
Chemoradiotherapy plus pembrolizumab (group A)	21 (38.2)
Neoadjuvant therapy plus surgery (group B)	20 (36.4)
Chemotherapy plus pembrolizumab (group C)	14 (25.5)

Citation: Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656
URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5641